Drug Profile
IP 889
Alternative Names: IP889Latest Information Update: 01 Mar 2013
Price :
$50
*
At a glance
- Originator Iroko Pharmaceuticals
- Class Analgesics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Osteoarthritis
Most Recent Events
- 01 Mar 2013 Discontinued - Phase-III for Osteoarthritis in USA (unspecified route)
- 06 May 2011 Phase-III clinical trials in Osteoarthritis in USA (unspecified route)